article thumbnail

Data breach at pharma partner Cencora puts sensitive patient information at risk

Fierce Pharma

A data breach at drug distributor Cencora has left sensitive information vulnerable, with patients on medicines from a dozen drugmakers potentially affected. | The potentially compromised data included patient information such as names and addresses, Cencora disclosed in letters to patients who may have been affected.

Patients 322
article thumbnail

Boehringer Ingelheim cuts monthly out-of-pocket inhaler prices to $35 for US patients

Fierce Pharma

As one of Boehringer Ingelheim's asthma competitors catches scrutiny over pricing and access concerns, the company itself is taking steps to cut patient costs in the U.S. Starting on June 1, patients will only have to shell out a maximum of $35 per month for Boehringer Ingelheim inhalers in the U.S.

Patients 317
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

J&J's patient assistance program suffers data breach, IBM says

Fierce Pharma

IBM disclosed "unauthorized access" to J&J’s Janssen CarePath patient assistance program, which helped over 1 million U.S. patients last year.

Patients 336
article thumbnail

Too many patients aren’t filling their prescriptions. Here’s how the industry can change that.

Fierce Pharma

Medication adherence is a large and growing challenge for pharma companies, healthcare providers and the patients they serve. Research shows that 20% of patients have failed to fill a script in the past, and one-third aren’t confident managing their illness. Engaging patients from the moment a drug is prescribed can help.

article thumbnail

The New Clinical Trial Supply Chain: Resilient, Flexible, and Patient-Centric

An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays.

article thumbnail

What Hospitals Need to Know about Patient Trust in GenAI

MedCity News

Hospitals need to start thinking about ways to build patients’ trust in generative AI in order for the healthcare industry to fully harness the technology’s potential. They can do this through methods like having transparent conversations, asking for patients’ consent to use the tools and training models on internal data, experts said.

Patients 131
article thumbnail

In gene therapy race, bluebird leads Vertex in activating treatment centers but trails in patient starts

Fierce Pharma

While Vertex leads in patient starts, bluebird has activated more treatment centers. It’s not an easy question to answer.

Leads 284
article thumbnail

Making the Case for Case Management for Cell and Gene Therapies

Deviations from the intended supply chain can delay timelines and affect these high value products, which can be detrimental to budgets, but more importantly can have dire effects on the patients whose lives depend on receiving these critical doses safely and on time.

article thumbnail

Running Decentralized Trials at Scale: Planning for Success

The potential for reaching a larger pool of recruits is possible when sponsors can bring more trial activities to the patient. There’s been a rapid shift towards decentralization in clinical trials & it’s clear why.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. Clinical trial data management is increasingly challenging as studies grow in complexity. In this paper, we explore real-time data access and analysis for proactive study management.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

Learning Objectives: Dose-response curves and patient treatment: How do pharmacologic and toxicologic principles apply to the dosing of drugs in clinical development? Ben Locwin will discuss the potential effects of this draft, along with the pharmacological and toxicological considerations for optimizing doses of prescription drugs.